Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377312 · ClinicalTrials.gov registry record · Early Phase 1
7 Day Continuous Parathyroid Hormone IV Infusion
A Early Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT00377312 is a Early Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 11 participants.
The verdict
NCT00377312, a Early Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Study consists of an eight day inpatient visit on the General Clinical Research Center. The investigators' specific aims are to: 1. To define the maximum safe dose of a seven day continuous administration of parathyroid hormone \[PTH(1-34)\] in healthy human volunteers. 2. To estimate the effect of a seven day continuous administration of parathyroid Hormone (PTH) in escalating doses on vitamin D metabolism, markers of bone turnover and fractional excretion of urine.
Interventions
- DRUG Parathyroid Hormone (1-34)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00377312
The ClinicalTrials.gov registry entry for NCT00377312 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Parathyroid Hormone (1-34) is the first listed.
NCT00377312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00377312 about?
NCT00377312 is a clinical study titled "7 Day Continuous Parathyroid Hormone IV Infusion". Study consists of an eight day inpatient visit on the General Clinical Research Center. The investigators' specific aims are to: 1. To define the maximum safe dose of a seven day continuous administration of parathyroid hormone \[PTH(1-34)\] in healthy human volunteers. 2. To estimate the effect of...
What is the current status of trial NCT00377312?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2006-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00377312?
The interventions under investigation include: Parathyroid Hormone (1-34) (DRUG).
Who is sponsoring clinical trial NCT00377312?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.